文献速递瓣膜病与结构性心脏病

外科主动脉瓣置换术后的预期寿命与手术风险及年龄的关系

Life Expectancy After Surgical Aortic Valve Replacement.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

该研究纳入8353例≥60岁接受孤立性生物瓣SAVR的主动脉瓣狭窄患者,按手术风险分层,低危占85.1%,中危11.3%,高危3.5%。低、中、高危患者中位生存期分别为10.9、7.3、5.8年,5年累积死亡率分别为16.5%、30.7%、43.0%。年龄仅与低危患者的5年死亡率相关(交互P<0.001)。

要点

  • 低危患者中位生存10.9年,中危7.3年,高危5.8年
  • 低危患者5年累积死亡率16.5%,中危30.7%,高危43.0%
  • 年龄仅影响低危患者的5年死亡率(交互P<0.001)

核心结论

  • 85%接受生物瓣SAVR的患者为低手术风险,SAVR后估计生存期可观,尤其年轻低危患者,应在心脏团队讨论中考虑。

研究设计与样本

  • 回顾性队列研究,纳入8353例≥60岁主动脉瓣狭窄接受孤立性生物瓣SAVR患者,使用logistic EuroSCORE(2001-2011)或EuroSCORE II(2012-2017)术前风险分层为低、中、高危。

主要发现

  • 低危7123例(85.1%),中危942例(11.3%),高危288例(3.5%)。
  • 低危中位生存期10.9年(95%CI 10.6-11.2),中危7.3年(7.0-7.9),高危5.8年(5.4-6.5)。
  • 低危5年累积死亡率16.5%(15.5%-17.4%),中危30.7%(27.5%-33.7%),高危43.0%(36.8%-48.7%)。
  • 低危患者中,60-64岁中位生存期16.2年,≥85岁6.1年。
  • 年龄仅与低危患者5年死亡率相关(交互P<0.001)。

临床怎么用

  • 心脏团队讨论SAVR与TAVI选择时,应参考基于手术风险和年龄的SAVR后预期寿命数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Surgical risk, age, perceived life expectancy, and valve durability influence the choice between surgical aortic valve replacement (SAVR) and transcatheter aortic valve implantation. The contemporaneous life expectancy after SAVR, in relation to surgical risk and age, is unknown. OBJECTIVES: The purpose of this study was to determine median survival time in relation to surgical risk and chronological age in SAVR patients. METHODS: Patients ≥60 years with aortic stenosis who underwent isolated SAVR with a bioprosthesis (n = 8,353) were risk-stratified before surgery into low, intermediate, or high surgical risk using the logistic EuroSCORE (2001-2011) or EuroSCORE II (2012-2017) and divided into age groups. Median survival time and cumulative 5-year mortality were estimated with Kaplan-Meier curves. Cox regression analysis was used to further determine the importance of age. RESULTS: There were 7,123 (85.1%) low-risk patients, 942 (11.3%) intermediate-risk patients, and 288 (3.5%) high-risk patients. Median survival time was 10.9 years (95% confidence interval: 10.6-11.2 years) in low-risk, 7.3 years (7.0-7.9 years) in intermediate-risk, and 5.8 years (5.4-6.5 years) in high-risk patients. The 5-year cumulative mortality was 16.5% (15.5%-17.4%), 30.7% (27.5%-33.7%), and 43.0% (36.8%-48.7%), respectively. In low-risk patients, median survival time ranged from 16.2 years in patients aged 60 to 64 years to 6.1 years in patients aged ≥85 years. Age was associated with 5-year mortality only in low-risk patients (interaction P < 0.001). CONCLUSIONS: Eighty-five percent of SAVR patients receiving bioprostheses have low surgical risk. Estimated survival is substantial following SAVR, especially in younger, low-risk patients, which should be considered in Heart Team discussions.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Martinsson A, Nielsen SJ, Milojevic M, et al. Life Expectancy After Surgical Aortic Valve Replacement. J Am Coll Cardiol. 2021. PMID: 34823657. doi:10.1016/j.jacc.2021.09.861

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。